Milestone Pharmaceuticals is back in focus as updated fair value estimates move from US$5.71 per share to US$4.57, a cut of roughly 20% in the latest pricing work. Recent research points to optimism around Cardamyst’s long term potential along with concern about launch momentum and reimbursement, which helps explain why many price targets now cluster between US$3 and US$5. In the sections that follow, you will see how these shifting targets fit into the broader Milestone Pharmaceuticals story...
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Adminis
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences. Conference Details Wells Fargo 21st Annual Healthcare Conference Format:Fireside chat and 1x1sPresentation Date:September 8, 2026Time:1:30 pm ETLocation:Bos
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and WorkMONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) af
Milestone Pharmaceuticals Inc (NASDAQ:MIST) shares gained 3. 9% on Friday after the company announced that the first patient had been enrolled in its Phase 3 ReVeRA-301 study of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR).
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular Rate and Improved Both Symptom Relief and Treatment Satisfaction in AFib-RVR Population MONTREAL and CHARLOTTE, N.C., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of
This is the newest page. Registered accounts read further back.